ALHC Price Prediction Next Week
Analysis and Insights
News Sentiment and Insider Activity:
Recent insider activity shows significant selling by high-level executives, including the Chief Human Resources Officer and Chief Medical Officer, who sold shares worth approximately $82,561 and $460,300, respectively. This represents a lack of confidence in the stock's short-term appreciation and could signal internal concerns about the company's performance.
Technical Indicators:
- RSI (6, 12, 14): The RSI values of 86.04, 74.72, and 72.74 indicate overbought conditions, suggesting potential pullback.
- MACD: The MACD line is above the signal line, indicating bullish momentum, but the histogram is weakening.
- Stochastic Oscillator: Overbought conditions with %K and %D both above 90.
- Fibonacci Levels: Resistance at $17.40 and $18.13, with support at $15.05 and $14.32.
Price Action and Volume:
The stock closed at $17.36 on March 24, with moderate volume of 784,229 shares. The price is currently testing the Fibonacci pivot level of $16.22, which could act as a support level.
Analyst and Institutional Sentiment:
- Analyst Ratings: 2 buy ratings and 1 sell rating, with an average target price of $16.41.
- Institutional Activity: 105 institutions increased positions, while 54 decreased theirs, indicating mixed sentiment.
Conclusion:
Based on the overbought RSI, weakening MACD, and significant insider selling, the stock is likely to face resistance at $17.40. The next trading week could see a pullback to $16.80, with potential support at $16.22.
Recommendation: Sell ALHC with a target price of $16.80.
ALHC Similar Chart Price Prediction
The price of ALHC is predicted to go up 14.16%, based on the high correlation periods with IDYA. The similarity of these two price pattern on the periods is 97.3%.
ALHC
IDYA
Up: 14.16%Similarity: 97.3%
ALHC Revenue Forecast
ALHC EPS Forecast
ALHC FAQs
What is ALHC revenue forecast for next quarter？
What is ALHC eps forecast for next quarter？
ALHC Analyst's Forecast
Jessica Tassan
Piper Sandler
Buy
2025-03-04
Price Target
$14 → $21
Upside
+33.67%
Piper Sandler raised the firm's price target on Alignment Healthcare to $21 from $14 and keeps an Overweight rating on the shares. The Alignment flywheel is gaining momentum across states, the firm says. It consists of repeatable, scalable processes and protocols that advance the four foundational goals of MA, namely expand beneficiary choice/ access, improve experience, optimize clinical outcomes, and control costs, Piper adds. The flywheel's repeatable, scalable processes and protocols establish local care delivery infrastructure and coordination, engage patients, close gaps, reduce inpatient admissions, boost quality and garner best-in-class Star Ratings for Alignment's contracts, in the firm's view.
Craig Jones
Stifel
Strong Buy
2025-01-14
Price Target
$14 → $16
Upside
+20.39%
Scott Fidel
Stephens & Co.
Buy
2025-01-02
Price Target
$17
Upside
+45.3%
